D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 25 2025
0mins
Source: Benzinga
Top Performing Mid-Cap Stocks: D-Wave Quantum Inc. saw a 53.47% increase after launching its Advantage2 quantum system, while Regencell Bioscience Holdings and Advance Auto Parts also experienced significant gains of 42.49% and 38.94%, respectively, following positive company announcements.
Other Notable Stock Increases: Merus N.V. rose by 32.68% due to promising clinical trial data, Oklo Inc. gained 29.56% amid regulatory easing reports, and several other mid-cap stocks like Sibanye-Stillwater Limited and BGM Group Ltd. also showed strong performance last week.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: Several publicly traded companies, including Regencell Bioscience Holdings and SES AI Corporation, are facing class action lawsuits for allegedly making false or misleading statements, with investors required to file lead plaintiff motions by specified deadlines to protect their rights.
- Regencell Bioscience Allegations: From October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny, thereby impacting its reputation and financial stability.
- SES AI Lawsuit Details: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, failing to disclose logistics constraints that affected Q4 2025 revenues, raising doubts about its growth prospects for 2026 and undermining investor confidence.
- FS KKR and Graphic Packaging Allegations: FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, while Graphic Packaging faces significant negative impacts on its financial results due to inventory management issues and reduced demand, leading to misleading positive statements about its business operations.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose vulnerabilities to market manipulation, which exposed investors to substantial financial risks and harmed the company's reputation.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to significant legal, financial, and reputational harm for investors, reflecting deficiencies in the company's governance and compliance policies.
- Call to Action for Investors: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, with the law firm promising to charge fees only upon successful recovery, thereby reducing the financial burden on investors.
See More
Regencell Bioscience Faces Class Action Over Alleged Market Manipulation
- Market Manipulation Allegations: Regencell Bioscience is facing a class action lawsuit for alleged market manipulation, with plaintiffs claiming significant losses for investors who purchased shares between October 28, 2024, and October 31, 2025, particularly after the company disclosed a DOJ investigation, leading to an 18.56% drop in share price, equating to a $3.09 loss per share.
- Valuation Discrepancy: Despite having no revenue and an annual R&D expenditure of approximately $1 million, Regencell's market capitalization reached around $14 billion, making it one of only 20 companies in the Nasdaq Biotechnology Index with a higher valuation, highlighting a stark disconnect between its valuation and underlying business fundamentals.
- Price Surge and Risk Concealment: Regencell's stock price skyrocketed from under $0.30 to a high of $78.00 on June 17, 2025, representing a staggering 48,650% increase without any corresponding business developments, leading plaintiffs to argue that the company recklessly concealed its vulnerability to market manipulation.
- Legal Implications and Investor Rights: Following the disclosure of the DOJ investigation, the market began to reprice Regencell shares to reflect the true regulatory and legal risks, emphasizing that investors deserve transparency regarding such risks to safeguard their investment interests.
See More
Regencell Faces Class Action Lawsuit Amidst Stock Price Volatility
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 2024 and October 2025, seeking damages for violations of federal securities laws, highlighting significant investor dissatisfaction with corporate governance and transparency.
- Stock Price Volatility: Regencell's share price soared to $78.00 in June 2025, a staggering 48,650% increase from the start of the class period, but quickly plummeted to above $20.00, reflecting a lack of confidence in the company's fundamentals and potentially leading to substantial investor losses.
- Financial Concerns: As of June 2025, Regencell had only 12 employees and no marketable products, with R&D expenditures significantly below industry standards, indicating a fragile business model that may face regulatory and legal risks.
- Market Manipulation Risks: The lawsuit alleges that executives failed to disclose risks related to market manipulation, exacerbating stock price volatility and exposing investors to significant financial risks, which could lead to broader legal and reputational harm.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting significant investor concerns regarding the company's compliance and operational transparency.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose risks of market manipulation, which exposed investors to substantial financial risks and increased the likelihood of regulatory scrutiny.
- Legal Consequences Risk: Due to these false statements, Regencell may face significant legal, financial, and reputational harm, with investors being warned about the jeopardized safety of their investments, potentially leading to a broader crisis of trust in the market.
- Investor Action Call: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, reflecting a strong emphasis on corporate governance and transparency issues.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiffs by June 23, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no upfront fees or costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, showcasing its extensive experience and success in the field, which bolsters investor confidence.
- Case Details Unveiled: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks, and highlights the need for greater transparency and compliance from the company as investors suffered losses when the truth emerged.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: Several publicly traded companies, including Regencell Bioscience Holdings and SES AI Corporation, are facing class action lawsuits for allegedly making false or misleading statements, with investors required to file lead plaintiff motions by specified deadlines to protect their rights.
- Regencell Bioscience Allegations: From October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny, thereby impacting its reputation and financial stability.
- SES AI Lawsuit Details: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, failing to disclose logistics constraints that affected Q4 2025 revenues, raising doubts about its growth prospects for 2026 and undermining investor confidence.
- FS KKR and Graphic Packaging Allegations: FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, while Graphic Packaging faces significant negative impacts on its financial results due to inventory management issues and reduced demand, leading to misleading positive statements about its business operations.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose vulnerabilities to market manipulation, which exposed investors to substantial financial risks and harmed the company's reputation.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to significant legal, financial, and reputational harm for investors, reflecting deficiencies in the company's governance and compliance policies.
- Call to Action for Investors: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, with the law firm promising to charge fees only upon successful recovery, thereby reducing the financial burden on investors.
See More
Regencell Bioscience Faces Class Action Over Alleged Market Manipulation
- Market Manipulation Allegations: Regencell Bioscience is facing a class action lawsuit for alleged market manipulation, with plaintiffs claiming significant losses for investors who purchased shares between October 28, 2024, and October 31, 2025, particularly after the company disclosed a DOJ investigation, leading to an 18.56% drop in share price, equating to a $3.09 loss per share.
- Valuation Discrepancy: Despite having no revenue and an annual R&D expenditure of approximately $1 million, Regencell's market capitalization reached around $14 billion, making it one of only 20 companies in the Nasdaq Biotechnology Index with a higher valuation, highlighting a stark disconnect between its valuation and underlying business fundamentals.
- Price Surge and Risk Concealment: Regencell's stock price skyrocketed from under $0.30 to a high of $78.00 on June 17, 2025, representing a staggering 48,650% increase without any corresponding business developments, leading plaintiffs to argue that the company recklessly concealed its vulnerability to market manipulation.
- Legal Implications and Investor Rights: Following the disclosure of the DOJ investigation, the market began to reprice Regencell shares to reflect the true regulatory and legal risks, emphasizing that investors deserve transparency regarding such risks to safeguard their investment interests.
See More
Regencell Faces Class Action Lawsuit Amidst Stock Price Volatility
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 2024 and October 2025, seeking damages for violations of federal securities laws, highlighting significant investor dissatisfaction with corporate governance and transparency.
- Stock Price Volatility: Regencell's share price soared to $78.00 in June 2025, a staggering 48,650% increase from the start of the class period, but quickly plummeted to above $20.00, reflecting a lack of confidence in the company's fundamentals and potentially leading to substantial investor losses.
- Financial Concerns: As of June 2025, Regencell had only 12 employees and no marketable products, with R&D expenditures significantly below industry standards, indicating a fragile business model that may face regulatory and legal risks.
- Market Manipulation Risks: The lawsuit alleges that executives failed to disclose risks related to market manipulation, exacerbating stock price volatility and exposing investors to significant financial risks, which could lead to broader legal and reputational harm.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting significant investor concerns regarding the company's compliance and operational transparency.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose risks of market manipulation, which exposed investors to substantial financial risks and increased the likelihood of regulatory scrutiny.
- Legal Consequences Risk: Due to these false statements, Regencell may face significant legal, financial, and reputational harm, with investors being warned about the jeopardized safety of their investments, potentially leading to a broader crisis of trust in the market.
- Investor Action Call: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, reflecting a strong emphasis on corporate governance and transparency issues.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiffs by June 23, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no upfront fees or costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, showcasing its extensive experience and success in the field, which bolsters investor confidence.
- Case Details Unveiled: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks, and highlights the need for greater transparency and compliance from the company as investors suffered losses when the truth emerged.
See More
